These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Management of a neonate with diffuse cutaneous mastocytosis: Case report and literature review. Jenkinson HA; Lundgren AD; Carter MC; Diaz LZ; Levy ML Pediatr Dermatol; 2019 Jul; 36(4):486-489. PubMed ID: 30828864 [TBL] [Abstract][Full Text] [Related]
29. Mastocytosis cells bearing a c-kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis. Dror Y; Leaker M; Caruana G; Bernstein A; Freedman MH Br J Haematol; 2000 Mar; 108(4):729-36. PubMed ID: 10792276 [TBL] [Abstract][Full Text] [Related]
30. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. Lanternier F; Cohen-Akenine A; Palmerini F; Feger F; Yang Y; Zermati Y; Barète S; Sans B; Baude C; Ghez D; Suarez F; Delarue R; Casassus P; Bodemer C; Catteau A; Soppelsa F; Hanssens K; Arock M; Sobol H; Fraitag S; Canioni D; Moussy A; Launay JM; Dubreuil P; Hermine O; Lortholary O; PLoS One; 2008 Apr; 3(4):e1906. PubMed ID: 18404201 [TBL] [Abstract][Full Text] [Related]
31. Evolving insights into the synergy between erythropoietin and thrombopoietin and the bipotent erythroid/megakaryocytic progenitor cell. Papayannopoulou T; Kaushansky K Exp Hematol; 2016 Aug; 44(8):664-8. PubMed ID: 26773569 [TBL] [Abstract][Full Text] [Related]
33. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. Büttner C; Henz BM; Welker P; Sepp NT; Grabbe J J Invest Dermatol; 1998 Dec; 111(6):1227-31. PubMed ID: 9856847 [TBL] [Abstract][Full Text] [Related]
34. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Sperr WR; Walchshofer S; Horny HP; Födinger M; Simonitsch I; Fritsche-Polanz R; Schwarzinger I; Tschachler E; Sillaber C; Hagen W; Geissler K; Chott A; Lechner K; Valent P Br J Haematol; 1998 Dec; 103(3):740-9. PubMed ID: 9858225 [TBL] [Abstract][Full Text] [Related]
35. "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. Sotlar K; Saeger W; Stellmacher F; Stahmer J; Jäckle S; Valent P; Horny HP J Clin Pathol; 2006 Aug; 59(8):875-8. PubMed ID: 16873565 [TBL] [Abstract][Full Text] [Related]
36. Comparison of lesional skin c-KIT mutations with clinical phenotype in patients with mastocytosis. Chan IJ; Tharp MD Clin Exp Dermatol; 2018 Jun; 43(4):416-422. PubMed ID: 29350409 [TBL] [Abstract][Full Text] [Related]
37. R634W KIT Mutation in an Adult With Systemic Mastocytosis. Astle JM; Rose MG; Racke FK; Tormey CA; Siddon AJ Lab Med; 2017 Aug; 48(3):253-257. PubMed ID: 28520972 [TBL] [Abstract][Full Text] [Related]
38. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114 [TBL] [Abstract][Full Text] [Related]
39. A new c-kit mutation in a case of aggressive mast cell disease. Pignon JM; Giraudier S; Duquesnoy P; Jouault H; Imbert M; Vainchenker W; Vernant JP; Tulliez M Br J Haematol; 1997 Feb; 96(2):374-6. PubMed ID: 9029028 [TBL] [Abstract][Full Text] [Related]
40. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Féger F; Ribadeau Dumas A; Leriche L; Valent P; Arock M Int Arch Allergy Immunol; 2002 Feb; 127(2):110-4. PubMed ID: 11919418 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]